Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Cancers, Free Full-Text

ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations

Advances in the treatment of metastatic prostate cancer: Trends in Cancer

Guidelines for Management of treating Rucaparib

Accelerating precision medicine in metastatic prostate cancer

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Rucaparib vs. Investigator choice - Problems with TRITON-3

Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer - Southern Iowa Mental Health Center

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Rucaparib provides better survival than usual care in metastatic prostate cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe

Novel therapies are changing treatment paradigms in metastatic prostate cancer, Journal of Hematology & Oncology